Privia Health Group (PRVA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
6 Aug, 2026Executive summary
Achieved strong operational execution in Q2 2026, with revenue up 21.4% to $632.6M, net income up 236.7% to $9.0M, and adjusted EBITDA up 29.1% to $37.4M.
Implemented providers grew 10.1% to 5,644 and attributed lives increased 19.2% to 1.65M, driven by organic growth and acquisitions.
Expanded into New Jersey, marking presence in 25 states and D.C., and integrated recent acquisitions.
Practice collections for Q2 reached $970M, up 12.4% year-over-year; six-month collections totaled $1.88B, up 13.4%.
Raised 2026 outlook across all key financial metrics due to robust first-half performance.
Financial highlights
Q2 2026 revenue was $632.6M (+21.4%), net income $9.0M (+236.7%), and adjusted EBITDA $37.4M (+29.1%).
Practice collections for Q2 were $970M (+12.4%); six-month collections $1.88B (+13.4%).
Care margin for Q2 was $132.1M (+14.7%), platform contribution margin 52.2%, and adjusted EBITDA margin 28.3%.
Ended Q2 with $412.2M in cash and no debt.
Net income per share for Q2 was $0.07 (basic/diluted); adjusted net income per share (diluted) was $0.19.
Outlook and guidance
Full-year 2026 guidance raised for revenue ($2.35B–$2.45B), care margin ($515M–$530M), and adjusted EBITDA ($145M–$155M).
Implemented providers guidance: 5,900–6,000; attributed lives: 1.625–1.65M.
Expect 70–80% of adjusted EBITDA to convert to free cash flow, subject to MSSP cash settlement timing.
Guidance does not assume new business development activity.
Latest events from Privia Health Group
- Raised 2024 guidance after strong Q3 growth, robust cash flow, and Indiana market entry.PRVA
Q3 20248 Jul 2026 - Q3 2025 revenue up 32.5%, net income up 94.1%, and FY 2025 guidance raised after strong growth.PRVA
Q3 20251 Jul 2026 - Q1 revenue up 25.8%, adjusted EBITDA up 36.3%, and guidance raised for attributed lives.PRVA
Q1 202613 May 2026 - 2025 outperformance and 2026 guidance highlight robust growth, cash flow, and strategic expansion.PRVA
Q4 20256 Apr 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.PRVA
Proxy filing2 Apr 2026 - Proxy covers director elections, executive pay, auditor ratification, and strong ESG and governance.PRVA
Proxy filing2 Apr 2026 - Q2 2024 delivered strong growth, raised guidance, and maintained a robust cash position.PRVA
Q2 20242 Feb 2026 - Tech-enabled platform drives profitable growth and high retention in value-based care.PRVA
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Record provider adds, robust cash flow, and expanding value-based care support 20%+ EBITDA growth.PRVA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026